Skip to main
ENTX

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio is a clinical-stage biopharmaceutical company with a strong product pipeline addressing unmet needs in various chronic medical conditions. The recent equity financing of $10 million and the potential for an additional $14.5 million from warrant exercise provides the company with a solid runway for its pivotal program initiation. With a valuation of $750 million and a price objective of $9 per share, there is significant upside potential for investors. However, risks to achieving this price target include clinical development delays, negative results from pivotal studies, and slow uptake in the market for its products. The recent key opinion leader webinar highlighted the vast market for Entera Bio's products and the potential for high adoption rates among prescribing physicians. This further strengthens the positive outlook for the company and its potential for success in the future.

Bears say

Entera Bio is a biopharmaceutical company with a negative outlook, due to concerns about the potential commercial performance of its product candidates. While their treatments for osteoporosis, hypoparathyroidism, obesity, and short bowel syndrome may have positive clinical results, the need for daily or weekly injections may deter patients and limit the market potential. Additionally, the company's plans to enter clinical trials for its next-generation formulation may delay the potential launch of its product until 2029, further hindering its commercial success.

ENTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, ENTX has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.